Please provide your email address to receive an email when new articles are posted on . “The efficacy of SARS-CoV-2 vaccines in patients treated with immunosuppressive therapies remains uncertain. ...

Please provide your email address to receive an email when new articles are posted on . Under Medicare Part D drug benefits, the biosimilar infliximab-dyyb was only 18% less expensive than the ...

Infliximab is a medication used to reduce the symptoms and signs of several chronic inflammatory disorders. It is approved for the treatment of Crohn’s disease, rheumatoid arthritis, psoriasis, ...

Intensified or accelerated dosing regimens with infliximab (Remicade) did not improve outcomes compared with the standard regimen in patients with steroid-refractory acute severe ulcerative colitis ...

Switching between infliximab biosimilar SB2 and the reference product did not affect clinical disease activity or safety in IBD patients. No significant changes were observed in clinical outcomes, ...

Infliximab is a monoclonal antibody, prescribed for autoimmune disorders, joint pain, Crohn's disease, inflammatory bowel disease, ankylosing spondylitis, psoriasis. The risk or severity of adverse ...

Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for ...

Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, according to research ...

Ulcerative colitis (UC) is one of the main forms of inflammatory bowel disease (IBD). UC causes the colon and rectum to become inflamed and ulcerated. Inflammation is the process by which the body ...

Psoriatic arthritis (PsA) is an inflammatory joint disease that has been associated with progressive joint damage and increased morbidity. In the first Infliximab Multinational Psoriatic Arthritis ...

Studies have shown that treatment with tumor necrosis factor inhibitors results in sustained improvements in the signs and symptoms of rheumatoid arthritis (RA). Infliximab, a chimeric monoclonal anti ...

An infliximab biosimilar (infliximab-axxq) delivered via subcutaneous injection was superior to intravenous vedolizumab (Entyvio) for induction and maintenance therapy of Crohn's disease (CD), ...